Food and Drug Administration approved rosuvastatin (Crestor) for reducing the likelihood of a heart attack or stroke or the need for a procedure to treat blocked or narrowed arteries in patients who have never been told they have heart disease but are nevertheless at increased risk of a cardiac event. 3 The target population included men older than 50 years and women older than 60 years with elevated levels of high-sensitivity C-reactive protein and an additional CVD risk factor such as smoking, hypertension, a family history of premature CVD, or low levels of high-density lipoprotein (HDL) cholesterol. 4 Computational studies concluded that a "treat-all" approach to CVD prevention is cost-effective.
5---7 However, misgivings over widespread statin use have been expressed on the basis of overall societal impact, including cost and toxicity, especially with the extension of treatment to children. 8---10 The wholesale cost of a 40-milligram rosuvastatin tablet at a local pharmacy recently was $4.22. The clinical benefits of statins relate to their ability to reduce cholesterol levels by inhibiting the rate-limiting cholesterol biosynthetic enzyme 3-hydroxy-3-methylglutaryl-CoA reductase. 1 
24---35
Mascitelli and Goldstein provided evidence that the beneficial effects of statins may result from their ability to favorably alter iron homeostasis. 36 Pathologic cellular iron retention has been implicated in systemic oxidative stress, vascular inflammation, and atherogenesis. Statins reduce ferritin levels in patients with advanced CVD, 37---39 renal disease, 40 and diabetes. 41 Data from a randomized trial of iron (ferritin) reduction (the Iron and Atherosclerosis Study [FeAST] ) in participants with advanced peripheral arterial disease (PAD) showed significant improvement in all-cause mortality and combined death plus nonfatal myocardial infarction and stroke with iron reduction. 42 There is evidence suggesting that iron reduction may provide an alternative to statins for reducing inflammation associated with atherosclerosis.
METHODS
The data we collected prospectively from FeAST allowed us to compare the effects of HDL/low-density lipoprotein (LDL) ratios versus those of ferritin levels (both randomization variables) on clinical outcomes. We searched FeAST data to test our hypothesis that clinical benefits of statins might be correlated with effects on iron homeostasis rather than cholesterol levels.
The Veterans Affairs Cooperative Studies Program supported FeAST, a prospective, randomized, controlled, single-blind clinical trial of iron reduction by graded phlebotomy. 42, 43 We tested the hypothesis that improved clinical outcomes might be achieved by reducing iron stores, represented by the serum ferritin, to levels typical of children and premenopausal women (about 25---50 ng/mL). 44 The consolidated standards of reporting trials diagram, study design, informed consent procedures, and other methodological details have been described in detail elsewhere. 42, 43 The majority of the 1277 participants (average age = 67 years) were male, and all participants were patients with PAD who were cancer-free on entry.
42,43
We used the entry ferritin level to calculate the amount of blood to be removed to target a trough ferritin level of about 25 nanograms per milliliter in participants randomized to iron reduction. We measured ferritin levels and HDL/LDL ratios (both were randomization
Objectives. We postulated the existence of a statin-iron nexus by which statins improve cardiovascular disease outcomes at least partially by countering proinflammatory effects of excess iron stores.
Methods. Using data from a clinical trial of iron (ferritin) reduction in advanced peripheral arterial disease, the Iron and Atherosclerosis Study, we compared effects of ferritin levels versus high-density lipoprotein to low-density lipoprotein ratios (both were randomization variables) on clinical outcomes in participants receiving and not receiving statins.
Results. Statins increased high-density lipoprotein to low-density lipoprotein ratios and reduced ferritin levels by noninteracting mechanisms. Improved clinical outcomes were associated with lower ferritin levels but not with improved lipid status.
Conclusions. There are commonalities between the clinical benefits of statins and the maintenance of physiologic iron levels. Iron reduction may be a safe and low-cost alternative to statins. (Am J Public Health. Published online ahead of print February 14, 2013: e1-e8. doi:10.2105/AJPH.2012.301163) variables) 43 in all participants at 6-month follow-up visits. We used 6-month ferritin levels to calculate the amount of blood to be removed to maintain the targeted reduced iron status in patients randomized to iron reduction. We subjected the effects of variables of interest on the primary end point, all-cause mortality, to intent-to-treat analysis. 42 linear regression analysis showed no relationship between mean follow-up HDL/LDL ratios and mean follow-up ferritin levels either for all participants combined (P = .89; Figure 1 ) or for participants randomized to iron reduction (P = .58). Using linear regression analysis, we noted a significant association between mean follow-up ferritin level and the log-relative hazard for all-cause mortality as described previously for the entire study cohort (P = .037) as well as for participants randomized to iron reduction (P = .028).
42
By contrast, from the Cox proportional hazard regression model, we did not find a relationship between the mean follow-up HDL/LDL ratios versus the log-relative hazard for all-cause mortality for the entire cohort (HR = 1.01; 95% CI = 0.89, 1.16; P = .84; Figure 2 ). Previous Kaplan---Meier analysis of mortality for the entire study cohort comparing patients having mean follow-up ferritin level above versus below the median of the means also showed significantly improved survival for participants with lower ferritin levels (P = .003).
42 Kaplan---Meier analysis of mean follow-up HDL/LDL ratios comparing patients having ratios above versus below the median of the means showed no effect of increasing mean follow-up HDL/LDL ratio on mortality ( Figure 3 ).
DISCUSSION
We found that improved cholesterol fractions and reduced ferritin levels with statin treatment appear to occur by noninteracting mechanisms (Figure 1 ). Reduced ferritin levels related significantly to improved outcomes in FeAST, 42 whereas improved HDL/LDL ratios had no effect on outcomes (Figures 2 and 3 ).
To some extent, statin use during this trial may have contributed to outcomes; however, control participants would likely have benefitted more because they received statins significantly more frequently than did iron reduction participants. Improved outcomes with iron reduction regardless of statin use 42 suggest that iron reduction rather than altered lipid status was the more powerful-or possibly the solecontributor to improved outcomes in FeAST. It also seems likely that statin benefits relate, at least in part, to reduction of iron-catalyzed oxidative stress and inflammation rather than to improved lipid status.
25---28,47---53
We compared effects on clinical outcomes of follow-up levels of cholesterol fractions versus ferritin levels 42, 43 and found that reduction of iron stores improved outcomes whereas improvement of cholesterol levels over time did not. Favorable effects of statins on iron homeostasis suggested the existence of a relationship, a statin---iron nexus, possibly accounting for statin benefits in the absence of hyperlipidemia. 36 The existence of this relationship appears to be supported by basic, pathophysiologic, and epidemiological observations as well as by clinical trial data.
Statins, Iron Homeostasis, and Inflammation
Statins may improve CVD outcomes by correcting abnormal cellular iron homeostasis through the induction of heme oxygenase (HO)-1 and inhibition of hepcidin expression.
36
The rate-controlling enzyme of heme catabolism, HO-1, counteracts oxidative endothelial damage leading to the inception and progression of atherosclerosis.
54---56 HO-1---mediated heme degradation is key to mobilization and extrusion of macrophage iron. HO-1 inhibition results in cellular loading of redox-active iron. 56 An extensive literature shows that the antiinflammatory properties of statins result from their ability to induce HO-1 expression.
47---53
Statins may be effective in CVD in part because they increase HO-1 expression 47---53 to protect arteries from further oxidative damage by mobilizing and removing plaque iron. 57 Hepcidin, the key hormonal regulator of iron distribution, binds to the cell membrane iron export protein, ferroportin, causing internalization and degradation of the hepcidin---ferroportin complex, resulting in macrophage iron retention. 58 Reduced hepcidin levels enhance iron export, thus reducing macrophage iron. 58 Foam cell formation and subsequent atherosclerosis require retention of macrophage iron and cholesterol. 59---62 Patients at risk for Note. HDL = high-density lipoprotein; LDL = low-density lipoprotein. There was no difference between patients having mean follow-up HDL/LDL ratios above vs below the median of the means for the cohort (hazard ratio = 0.97; 95% confidence interval = 0.66, 1.41; P = .857). vascular disease express elevated hepcidin levels with increased macrophage iron; both hepcidin and macrophage iron levels are associated with the presence of carotid plaques. 63 Pharmacologic inhibition of hepcidin experimentally also enhances efflux of macrophage cholesterol and iron to inhibit foam cell formation and atherosclerosis. 64 Hepcidin overexpression promotes plaque destabilization and increased inflammatory cytokine release, intracellular lipid and iron accumulation, oxidative stress, and macrophage apoptosis in an experimental model of accelerated atherosclerosis. 65 Adverse effects of hepcidin can be negated by blocking hepcidin expression as well as by iron chelation. 65 Statins reduced hepcidin levels, 66 whereas iron administration increased hepcidin levels.
67
Numerous studies have shown that iron in physiologic excess promotes oxidative stress, 30---35 which is inhibited by statins.
24---28
Statins exert antioxidant and anti-inflammatory effects by inhibiting the generation of reactive oxygen species. 
Commonality of Effects of Statins and Low Iron Status
An extensive literature further suggests commonalities between statin effects and lower iron status. The data sources we reviewed included MEDLINE, Scopus, and the Cochrane Library. We searched these sources for prior reports of statin---iron relationships and possible mechanisms underlying ferritin reduction in participants receiving statins, using the following terms: statin---cardiovascular mortality mesh, iron metabolism---HO mesh, hepcidin, macrophage iron, foam cell atherosclerosis ferroportin, and ferritin. We evaluated design methodology, criteria for defining data quality and report selection, and corresponding terminology using prior guidelines. 87, 88 Level A data from prospective randomized trials of statins 1 Epidemiological studies show that low levels of body iron, measures of systemic oxidative stress, and C-reactive protein characterize individuals consuming a Mediterranean-style diet. 89 These individuals exhibit a lower morbidity and greater longevity than does the Northern European population. 89 Lower ferritin levels typical of frequent blood donors are also associated with a reduced risk of cardiac events and overall superior health. Lower ferritin levels in premenopausal women and elderly men coincide with evidence that those questioning statin efficacy in these individuals have provided.
128, 129
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The FeAST Data
FeAST trial findings described previously support an association between lower ferritin levels and greater longevity. 42 Regression plots of follow-up ferritin levels versus study outcomes in control and iron reduction participants combined showed significant protective effects of lower iron burden against death and nonfatal myocardial infarction and stroke. 
Implications of the Statin-Iron Nexus
The proposal of the existence of a statin---iron nexus results from evidence that statins alter iron homeostasis 47---56 and that both statins and lower ferritin levels appear to be effective in reducing oxidative stress and associated inflammation, resulting in improved clinical outcomes. Certain statin effects appear to be mediated by mechanisms similar to iron reduction. FeAST data suggest that improved cholesterol fractions and reduced ferritin levels with statin treatment occur by noninteracting mechanisms (Figure 1 ). Lower ferritin levels were associated with significantly better outcomes in FeAST, 42 whereas higher, presumably better, HDL/LDL ratios were not (Figures 2 and 3 138, 141, 146 Confirmation of the efficacy of iron reduction might point the way to management of CVD using appropriate dietary measures. An analysis of public policies that affect chronic nutritional iron overdosing is beyond the scope of our study; however, the Food and Drug Administration classification of iron supplements as "generally regarded as safe" may, in the absence of iron deficiency, be open to question. 147 The finding of a statin---iron nexus suggests the possibility of a low-cost and safe alternative to "treat-all" statin therapy.
3---7 Past confusion from negative epidemiological studies lacking appropriate comparator populations 148 could be resolved by prospective trials of iron reduction in at-risk populations. Favorable outcomes might be attained without a need for universal drug treatment to achieve a low risk range for ferritin levels approximating 75 nanograms per milliliter or lower. 
